Praxis für Rheumatologie, Gastroenterologie und Innere Medizin
- Address
- lock Available on a paid plan
Immune System Diseases and Immune System Processes
At Praxis für Rheumatologie, Gastroenterologie und Innere Medizin in München, clinical research in this area focuses on systemic lupus erythematosus and other inflammatory conditions driven by immune activity. The trials are designed to evaluate new treatment options and measure whether they can better control disease activity.
- Research in systemic lupus erythematosus aimed at testing a new therapy for active disease
- Studies exploring immune-related inflammation and how it responds to treatment
These studies help assess whether emerging therapies can improve symptom control and overall disease management in people with complex autoimmune disorders.
Musculoskeletal Diseases
This site also conducts trials in rheumatologic conditions affecting the joints, spine, and muscles, including rheumatoid arthritis, axial spondyloarthritis, and polymyalgia rheumatica. The research is focused on finding better ways to reduce pain, stiffness, and inflammation while improving daily function.
- Studies in moderately active rheumatoid arthritis assessing whether a new treatment can improve disease control
- Trials in early axial spondyloarthritis evaluating treatment effectiveness in patients with inflammatory back disease
- Research in polymyalgia rheumatica looking at how to optimize steroid-based treatment
Overall, the work in this therapeutic area aims to refine treatment strategies for chronic inflammatory joint and muscle diseases.
Skin and Connective Tissue Diseases
Another important research focus is psoriatic arthritis, a condition that links joint inflammation with skin and connective tissue involvement. The trials at this site are evaluating new therapies and comparing them with existing options to understand how well they control active disease.
- Multiple studies in psoriatic arthritis assessing symptom improvement and disease response
- Research examining longer-term safety and tolerability of treatment for ongoing inflammatory disease
- Trials comparing new approaches with standard care to support better treatment selection
These investigations are intended to improve both short-term disease control and longer-term treatment confidence for patients living with persistent inflammatory arthritis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1MoonLake Immunotherapeutics AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Praxis für Rheumatologie, Gastroenterologie und Innere Medizin
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | MoonLake Immunotherapeutics AG | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clofutriben | 1 | Unknown | 2022-07-26 | 2022-07-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.